Neurodelta is a Leeds based research and development group that uses in silico identification of protein-protein interactions for subsequent development as models for drug and diagnostic discovery. The in silico identification techniques also aid in the design of specific peptide and nucleotide aptamers that recognise the specific molecular targets being studied. The original Neurodelta concept was developed by Dr Nat Milton in May 2003 when the original Neurodelta Ltd company was formed, based on his expertise in protein-protein interactions relevant to Alzheimer's disease. The current in silico bioinformatic research and development activity has focused on the in identification and characterisation of novel targets for anti-amyloid plus other protein targeting development activities, including targeting proteins involved in enzyme processing of endogenous mediators of amyloid toxicity. Studies have also involved identification of novel interactions of KiSS-1 metastasis suppressor protein products with Alzheimer's associated proteins.


A UK patent for the use of kissorphin peptides in the treatment of Alzheimer's disease, Creutzfeldt Jakob disease and Diabetes Mellitus has been granted to the University of Roehampton [GB2493313 Patent] and patent applications have also previously been filed by Insight Biotechnology Ltd based on Dr Milton's work using in silico and in vitro techniques. Amongst the compounds identified are amyloid-ß anti-sense peptides, phosphorylated amyloid-ß and KiSS-1 metastasis suppressor protein derived peptides. Amongst the compounds developed from these techniques is the R9 peptide, which inhibits catalase interactions with amyloid-ß fibrils, plus the kisspeptin and kissorphin peptides, which inhibit amyloid-ß, amylin and prion protein fragment induced neurotoxicity in vitro.

Bioinformatics protocols for non-commercial use are available at The commercial aspects of the groups work are handled by Neurodelta Ltd.